Adherence to HAART in French HIV-infected injecting drug users: The contribution of buprenorphine drug maintenance treatment

AIDS

Volumn 14, Issue 2, 2000, Pages 151-155

  Moatti, J P ^a,b   Carrieri, M P ^a   Spire, B ^a,f   Gastaut, J A ^a,c   Cassuto, J P ^d   Moreau, J ^e  

^a INSERM   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d University of Côte d'Azur   (France)

^e Hopital Felix Houphouet Boigny   (France)

^f OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

Author keywords

Adherence; Antiretroviral agents; Buprenorphine; Drug maintenance treatment

Indexed keywords

ANTIRETROVIRUS AGENT; BUPRENORPHINE; INDINAVIR; OPIATE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ADULT; AGE; ALCOHOL CONSUMPTION; AMBULATORY MONITORING; ARTICLE; COHORT ANALYSIS; DRUG DEPENDENCE; FEMALE; FRANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LIFE EVENT; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUESTIONNAIRE; REGRESSION ANALYSIS; VIRUS LOAD; VIRUS TITRATION;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; BUPRENORPHINE; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; NARCOTICS; PATIENT COMPLIANCE; QUESTIONNAIRES; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 0033996452     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200001280-00010     Document Type: Article

References (23)

1. 1. Mehta S, Moore RD, Graham NM. Potential factors affecting adherence with HIV therapy. AIDS 1997, 11:1665-1665.
2. 2. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998, 279:1977-1977.
3. 3. Sherer R. Adherence and antiretroviral therapy in injection drug users. JAMA 1998, 280:567-567.
4. 4. Moatti JP, Souville M, Escaffre N, Obadia Y. French general practitioners' attitudes toward maintenance drug abuse treatment with buprenorphine. Addiction 1998, 93:1567-1567.
5. 5. Sarason IG, Johnson JH, Siegel JM. Assessing the impact of life changes: development of the Life Experiences Survey. J Consult Clin Psychol 1978, 46:932-932.
6. 6. Lerner BH, Gulick RM, Dubler NN. Rethinking non-adherence: historical perspectives on triple-drug therapy for HIV disease. Ann Intern Med 1998, 129:573-573.
7. 7. Bangsberg D, Tulsky JP, Hecht FM, Moss AR. Protease inhibitors in the homeless. JAMA 1997, 278:63-63.
8. 8. Freeman RC, Rodriguez GM, French JF. Compliance with AZT treatment regimen of HIV-seropositive injection drug users: a neglected issue. AIDS Educ Prev 1996, 8:58-58.
9. 9. Sorensen JL, Mascovich A, Wall TL, DePhilippis D, Batki SL, Chesney M. Medication adherence strategies for drug abusers with HIV/AIDS. AIDS Care 1998, 10:297-297.
10. 10. Weidle P, Ganea CE, Ernst J. Multiple reasons for non-adherence to antiretroviral medications in an inner city minority population : need for multifaceted approach. XII International Conference on AIDS. Geneva, June 1998 [abstract 32360].
11. 11. Nieukwerk P, Gisolf EH, Leewen V, et al. Self-report adherence to ritonavir/saquinavir and ritonavir/saquinavir/stavudine in a randomized clinical trial : preliminary results. XII International Conference on AIDS. Geneva, June 1998 [abstract 32362].
12. 12. Kastrissios H, Suarez JR, Katzenstein D, Girard P, Sheiner LB, Blaschke TF. Characterizing patterns of drug-taking behaviour with a multiple drug regimen in an AIDS clinical trial. AIDS 1998, 12:2295-2295.
13. 13. Klaus BD, Grodesky MJ. Clinical implications of alcoholism in patients with HIV/AIDS. Nurse Pract 1997, 22:101-101.
14. 14. Souville M, Leport C, Raffi F, et al. Short-term HAAR-associated factors to compliance in an adult HIV-infected individuals cohort [in French]. Second Seminar of Clinical Research of ANRS. Paris, December 1998 [abstract A68].
15. 15. Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA 1998, 280:544-544.
16. 16. Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998, 280:547-547.
17. 17. Carrieri P MJ, Vlahov D, Obadia Y, Reynaud-Maurupt C, Chesney M and the MANIF 2000 Study group. Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. J Epidemiol Comm Health 1999, 53:4-4.
18. 18. Ross CE, Mirowsky JD. A comparison of life-event-weighting schemes : change, undesirability, and effect-proportional indices. J Health Soc Behav 1979, 20:166-166.
19. 19. Stroebe W, Stroebe MS. Social Psychology and Health. Buckingham: Open University Press; 1995.
20. 20. Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. New Engl J Med 1995, 333:751-751.
21. 21. Gourevitch MN, Wasserman W, Panero MS, Selwyn PA. Successful adherence to observed prophylaxis and treatment of tuberculosis among drug users in a methadone program. J Addict Dis 1996, 15:93-93.
22. 22. Wall TL, Sorensen JL, Batki SL, Delucchi KL, London JA, Chesney MA. Adherence to zidovudine (AZT) among HIV-infected methadone patients: a pilot study of supervised therapy and dispensing compared to usual care. Drug Alcohol Depend 1995, 37: 261-261.
23. 23. Sakol MS, Stark C, Sykes R. Buprenorphine and temazepam abuse by drug takers in Glasgow: an increase. Br J Addict 1989, 84:439-439.